Skip to main content

Advertisement

SpringerLink
Log in

Acute promyelocytic leukemia

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The treatment of acute promyelocytic leukemia (APL) is different from other subtypes of acute myelocytic leukemia (AML). All trans-retinoic acid (ATRA) is an essential component of the standard remission induction for all newly diagnosed APL patients. Remission induction with ATRA and chemotherapy given concurrently appears to be associated with fewer relapses. With further consolidation chemotherapy without high-dose cytosine arabinoside, the disease-free survival rate can reach 70% to 80%, and many of these patients are cured, more so than in any other AML subtype. APL is especially sensitive to anthracyclines, which should be included in the chemotherapy cycles at a higher dose than in other AML subtypes. Maintenance with low-dose chemotherapy (oral daily 6-mercaptopurine with weekly methotrexate) or ATRA further improves the long-term outcome. New approaches are also available for relapsing patients, although the optimal treatment is unknown. Patients who did not receive oral ATRA in first relapse can be treated with this agent, as can first relapsing patients who have been off the drug for more than 1 year. Because of poor remission rates, ATRA should not be used in patients with second or subsequent relapses (whether ATRA was given in the past), in patients with relapses early after ATRA discontinuation, or in patients relapsing while on ATRA therapy. Arsenic trioxide can also be used, especially in patients resistant to ATRA. Because arsenic trioxide is still experimental and not yet widely available, patients who are unlikely to respond to ATRA or who unsuccessfully undergo ATRA reinduction should be treated with chemotherapy. Patients in second or subsequent remission induced with ATRA or chemotherapy should receive consolidation chemotherapy. When arsenic trioxide is used for reinduction, the drug should be continued for several cycles; however, adding consolidation chemotherapy might improve the results. Because it is unknown whether APL in second or subsequent remission is curable with salvage therapy, allogeneic hematopoietic stem cell transplantation is often considered for patients with a human leukocyte antigen (HL-A)-identical sibling and autologous transplantation when a donor does not exist. However, compared with the new treatments, the role of transplantation for relapse is unclear. In first remission, there is no role for transplantation. A new liposomal formulation of intravenous ATRA is being investigated and seems effective in late first relapses, and it may be able to induce and maintain first remissions in selected patients without chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Melnick A, Licht JD: Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999, 93:3167–3215. An excellent review on the pathogenesis of acute promyelocytic leukemia for more in-depth reading.

    PubMed  CAS  Google Scholar 

  2. Grimwade D: The pathogenesis of acute promyelocytic leukemia: evaluation of the role of molecular diagnosis and monitoring in malignancy of the disease. Br J Haematol 1999, 106:591–613.

    Article  PubMed  CAS  Google Scholar 

  3. Stone RM, Mayer RJ: The unique aspects of acute promyelocytic leukemia. J Clin Oncol 1990, 8:1913–1921.

    PubMed  CAS  Google Scholar 

  4. Avvisati G, Mandelli F, Petti MC, et al.: Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Hematol 1990, 44:257–260.

    Article  CAS  Google Scholar 

  5. Head D, Kopecky KJ, Weick J, et al.: Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Southwest Oncology Group. Blood 1995, 86:1717–1728.

    PubMed  CAS  Google Scholar 

  6. Degos L, Dombret H, Chomienne H, et al.: Alltrans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995, 85:2643–2653.

    PubMed  CAS  Google Scholar 

  7. Tallman MS, Andersen JW, Schiffer CA, et al.: Alltrans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997, 337:1021–1026. This article gives the results of the randomized U.S. intergroup trial that established the role of ARTA in APL.

    Article  PubMed  CAS  Google Scholar 

  8. Asou N, Adachi K, Tamura J, et al.: Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol 1998, 16:78–85.

    PubMed  CAS  Google Scholar 

  9. Fenaux P, Le Deley MC, Castaigne S, et al.: Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group Blood 1993, 82:3241–3249.

    CAS  Google Scholar 

  10. Avvisati G, Lo Coco F, Diverio D, et al.: AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia. Blood 1996, 88:1390–1398.

    PubMed  CAS  Google Scholar 

  11. Fenaux P, Wattel E, Archimbaud E, et al.: Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia (letter). The French APL Group. Blood 1994, 84:666–667.

    PubMed  CAS  Google Scholar 

  12. Fenaux P, Chastang C, Chevret S, et al.: A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic Leukemia. Blood 1999, 94:1192–1200. Another very large randomized trial discussing the role of ATRA in induction and maintenance.

    PubMed  CAS  Google Scholar 

  13. Burnett AK, Goldtsone AH, Gray RG, Wheatley K: All trans retinoic acid given concurrently with induction chemotherapy improves outcome in APL: results of the UK MRC ATRA trial (abstract). Blood 1997, 90(suppl 1):330a.

    Google Scholar 

  14. Estey E, Thall PF, Pierce S, et al.: Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997, 15:483–490.

    PubMed  CAS  Google Scholar 

  15. Chen A, Xue YQ, Zhang R, et al.: A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991, 78:1413–1419.

    PubMed  CAS  Google Scholar 

  16. Chao N, Hua Y, Ting Y, et al.: Studies on treatment of acute promyelocytic leukemia with arsenic arioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94:3315–3324. A new study describing the effect of arsenic trioxide in newly diagnosed and relapsed APL patients.

    Google Scholar 

  17. Soignet S, Frankel S, Tallman M, et al.: U.S. multicenter trial of arsenic trioxide (at) in acute promyelocytic leukemia (APL) (abstract). Blood 1999, 94 (suppl 1):968a.

    Google Scholar 

  18. Meloni G, Diverio D, Marco Vignetti, et al.: Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR fusion gene. Blood 1997, 90:1321–1325.

    PubMed  CAS  Google Scholar 

  19. Diverio D, Rossi V, Avvisati G, et al.: Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter “AIDA” trial. GIMEMA-AIEOP Multicenter “AIDA” Trial. Blood 1998, 92:784–789.

    PubMed  CAS  Google Scholar 

  20. Lo Coco F, Diverio D, Avvisati G, et al.: Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999, 94:2225–2229. A good resource on molecular remission and relapse in APL.

    Google Scholar 

  21. Estey EH, Giles FJ, Kantarjian H, et al.: Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood 1999, 94:2230–2235. Use of intravenous liposomal ATRA and the ability to obtain long-term molecular remission without chemotherapy.

    PubMed  CAS  Google Scholar 

  22. Mandelli F, Labopin M, Granena A, et al.: European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT). Bone Marrow Transplant 1994, 14:293–298.

    PubMed  CAS  Google Scholar 

  23. Tallman MS, Andersen JW, Schiffer CA, et al.: Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000, 95:90–95.

    PubMed  CAS  Google Scholar 

  24. De Botton S, Dombret H, Sanz M, et al.: Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed. Blood 1998, 92:2712–2718.

    PubMed  Google Scholar 

  25. Muindi J, Frankel SR, Miller WH Jr, et al.: Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “dresistance” in patients with acute promyelocytic leukemia. Blood 1992, 79:299–306.

    PubMed  CAS  Google Scholar 

  26. Muindi JRF, Frankel SR, Huselton C, et al.: Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992, 52:2138–2146.

    PubMed  CAS  Google Scholar 

  27. Delva L, Cornic M, Balitrand N, et al.: Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993, 82:2175–2181.

    PubMed  CAS  Google Scholar 

  28. Camacho LH, Soignet SL, Heller G, et al.: Leukocytosis and the “retinoic acid syndrome” during induction treatment of acute promyelocytic leukemia with arsenic trioxide (abstract). Blood 1999, 94(suppl1):595a.

    Google Scholar 

  29. Giannì M, Koken MHM, Chelbi-Alix MK, et al.: Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998, 91:4300–4310.

    PubMed  Google Scholar 

  30. Mehta K, Sandeghi T, McQueen T, Lopez-Bernstein G: Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid. Leukemia Res 1994, 18:587–596.

    Article  CAS  Google Scholar 

  31. Estey E, Thall PF, Mehta K, Rosenblum M, et al.: Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood 1996, 87:3650–3659.

    PubMed  CAS  Google Scholar 

  32. Drach J, Lopez-Berestein G, McQueen T, et al.: Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res 1993, 53:2100–2119.

    PubMed  CAS  Google Scholar 

  33. Estey E, Douer D, Wiernick P, et al.: Treatment of recurrent acute promyelocytic leukemia with liposomal all trans retinoic acid (dabstract). Blood 1997, suppl 1:332a.

  34. Tobita T, Takeshita A, Kitamura K, et al.: Treatment with a new synthetic Retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 1997, 90:967–973.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Ave, 90033, Los Angeles, CA, USA

    Dan Douer MD

Authors
  1. Dan Douer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Douer, D. Acute promyelocytic leukemia. Curr. Treat. Options in Oncol. 1, 31–40 (2000). https://doi.org/10.1007/s11864-000-0013-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-000-0013-1

Keywords

Search

Navigation